The Future of
Life-saving Treatments
Vision & Mission
We create the future of life-saving treatments by aiming to reduce the organ shortage and speed up drug development by providing accessible life science solutions that combine biology and technology.
Say goodbye to
Animal Testing Manual Work Static Analysis


Automated Laboratory Workflows Through Bioconvergence
Learn how synergies between our technologies enable laboratories to develop new drugs faster and more cost efficient.
Bico by numbers
-
Net sales July-September 20230 MSEK
-
Organic growth July-September 20230 %
-
Employees0 +
-
Instruments in the field0 +
-
Publications0 +
-
Countries0 +
Products that Fuel Groundbreaking Scientific Discoveries













BICO News Feed
November 30, 2023
Cellink CELLINK and Ossiform Enter a Strategic Partnership to launch Ossi Ink, a printable bioink based on Ossiform’s P3D Bone material
Cellink CELLINK and Ossiform Enter a Strategic Partnership to launch Ossi Ink, a printable bioink based on Ossiform’s P3D Bone material
November 21, 2023
Cellenion Cellenion Launches proteoCHIP EVO 96 – Tailored for robust and high-throughput liquid chromatography
Cellenion Cellenion Launches proteoCHIP EVO 96 – Tailored for robust and high-throughput liquid chromatography
November 16, 2023
Scienion MEDICA 2023: reliable, versatile, and trusted solutions for innovative diagnostics
Scienion MEDICA 2023: reliable, versatile, and trusted solutions for innovative diagnostics
October 18, 2023
Cellink CELLINK Announces CELLINK Vivoink: Our First Medical-Grade Bioink
Cellink CELLINK Announces CELLINK Vivoink: Our First Medical-Grade Bioink
press releases
11/14/23RegulatoryPublication of BICO Group interim report July – September 2023
11/13/23BICO has divested Ginolis
11/09/23RegulatoryBICO Group AB Nomination Committee 2024 AGM appointed
11/01/23RegulatoryBICO releases preliminary revenue, EBITDA, and cash flow from operating activities for Q3, 2023
08/22/23RegulatoryPublication of BICO Group interim report April – June 2023
08/21/23RegulatoryBICO announces goodwill impairment predominantly due to increased WACC, and write-downs of assets
08/21/23RegulatoryMaria Forss is appointed new President and CEO of BICO Group AB (publ)
05/09/23RegulatoryBulletin from Annual General Meeting in BICO Group AB (publ)
05/04/23RegulatoryPublication of BICO Group interim report January – March 2023
04/04/23RegulatoryNotice to attend the Annual General Meeting in BICO Group AB (publ)
03/17/23RegulatoryBICO Publishes Annual Report and Sustainability Report 2022
02/27/23BICO introduces new life sciences manufacturing platform integrating ABB Robotics technology
02/22/23RegulatoryPublication of year-end Report January – December 2022
01/31/23RegulatoryBICO Group AB (publ) announces an increase in number of shares and votes
01/05/23RegulatoryBICO appoints COO
01/02/23RegulatoryBICO Group Appoints New CFO
12/30/22RegulatoryBICO Group AB (publ) announces an increase in number of shares and votes
12/14/22RegulatoryBulletin from Extraordinary General Meeting in BICO Group AB (publ)
12/08/22RegulatoryBICO agrees with Sartorius on strategic cooperation, followed by a SEK 487m directed share issue of shares to Sartorius
11/14/22RegulatoryNotice of extraordinary general meeting in BICO Group AB (publ)
11/10/22RegulatoryBICO Group announces new financial targets
11/09/22RegulatoryPublication of Interim Report January – September 2022
10/28/22RegulatoryBICO Group Nomination Committee 2023 AGM appointed
08/24/22RegulatoryPublication of Interim Report January – June 2022
07/15/22RegulatoryBICO announces preliminary financial performance for the second quarter
05/18/22RegulatoryBICO Publishes Interim Report January – March 2022: Continued growth in sales, improved profitability and focus on commercial synergies
05/12/22RegulatoryBICO Group adds senior IR manager to its executive management
05/02/22RegulatoryBusiness update for BICO Group AB (publ)
04/29/22New Interim CFO at BICO